serena-2: camizestrant vs fulvestrant in post-menopausal women with advanced er /her- breast cancer
Published 1 year ago • 236 plays • Length 4:06Download video MP4
Download video MP3
Similar videos
-
6:55
mafalda oliveira, sabcs 2022: camizestrant vs fulvestrant for advanced er her2- breast cancer
-
0:52
first-line camizestrant for er /her2- advanced breast cancer
-
6:23
alternate: fulvestrant and/or anastrozole in er her2- postmenopausal breast cancer
-
4:05
camizestrant may be superior to fulvestrant in patients with hr-positive, her2-negative bc
-
4:34
lasofoxifene vs fulvestrant for locally advanced/metastatic er /her2- breast cancer: elaine trial
-
17:10
sabcs 2022: results of the randomized, multi-dose phase 2 serena-2 trial
-
0:55
cambria-1: camizestrant vs standard endocrine therapy in breast cancer
-
10:15
monaleesa-3 os results: fulvestrant/ribociclib in postmenopausal hr /her2- advanced breast cancer
-
5:02
samuraciclib in combination with fulvestrant in patients with advanced hr /her2- breast cancer
-
7:26
s1222 hr , stage iv breast cancer: fulvestrant w/wo everolimus /- anastrozole
-
4:39
serd vs investigator’s choice of endocrine monotherapy for er /her2-advanced/mbc
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
2:46
ameera-3: amcenestrant does not improve pfs in er /her2- breast cancer
-
1:05
cambria 1: camizestrant er /her2- early breast cancer
-
1:15
treating breast cancer in premenopausal women
-
1:47
the capture clinical trial
-
0:30
the role of serds in the treatment landscape of patients with er /her2- breast cancer
-
2:49
neratinib, trastuzumab fulvestrant for her2-mutant, hr , metastatic breast cancer
-
2:27
capivasertib fulvestrant improves progression-free survival in advanced hr breast cancer patients